In a rare demonstration of bipartisanship during a House Committee on Oversight and Accountability hearing on May 23, Democrats and Republicans jointly voiced concern and disapproval—and sought answers—about the behind-the-scenes deal-making that results in consumer drug pricing the legislators say is unfair and unreasonably high. In fact, almost two-and-half hours into the hearing, first-term Rep….